Rolapitant: New add-on agent for chemotherapy-induced delayed nausea and vomiting
نویسندگان
چکیده
منابع مشابه
Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
Rolapitant is a highly selective neurokinin-1 receptor antagonist, orally administered for a single dose of 180 mg before chemotherapy with granisetron D1, dexamethasone 8 mg BID on day 2-4. It has a unique pharmacological characteristic of a long plasma half-life (between 163 and 183 hours); this long half-life makes a single use sufficient to cover the delayed emesis risk period. No major dru...
متن کاملDifferential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting
Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of many cytotoxic chemotherapy regimens. CINV typically manifests during two well-defined time periods (acute and delayed phases). The acute phase is the first 24 hours after chemotherapy and is largely managed with 5-hydroxytryptamine 3 receptor antagonists. The delayed phase, a 5-day at-risk period during which pati...
متن کاملChemotherapy-induced nausea and vomiting.
younger patient age, platinumor anthracyclinebased chemotherapy, low alcohol consumption, earlier cycles of chemotherapy, previous history of morning sickness, and prior emetic episodes after chemotherapy. The acute and delayed scoring systems both had good predictive accuracy when applied to the external validation sample (acute— auroc: 0.69; 95% confidence interval: 0.59 to 0.79; delayed—auro...
متن کاملChemotherapy-induced nausea and vomiting.
Chemotherapy-induced nausea and vomiting (CINV) affects many cancer patients and has a great influence on quality of life. CINV involves coordination of several organs of the gastrointestinal tract, the peripheral and central nervous systems. Many neurotransmitters are involved in this process, and the predominant receptors are serotonin, neurokinin-1 and dopamine receptors. Risk factors for CI...
متن کاملChemotherapy-Induced Nausea and Vomiting
In the past two decades, significant advances have been made in the management of chemotherapy-induced nausea and vomiting (CINV). These advances are primarily due to a greater understanding of the physiological and molecular pathways underlying CINV, which resulted in major progress in the management of patients with CINV. In the early 1990s, CINV treatment consisted of dex-amethasone [1]. Imp...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmacy Today
سال: 2015
ISSN: 1042-0991
DOI: 10.1016/s1042-0991(15)30122-5